BAL30072 is a new siderophore sulfactam antibiotic. The penicillin-binding-protein inhibition and its bactericidal mode of action confer potent in-vitro and in-vivo activity against Gram-negative bacteria. Pathogens such as
As per the agreement, the parties are expected to evaluate the potential utility of RXi’s proprietary rxRNA technology against specific miRNA targets of interest to miRagen in the
The LaPorte plant is a multi-purpose manufacturing facility specialising in the production of registered intermediates and active pharmaceutical ingredients (APIs) for the pharmaceutical industry. AMPAC Fine Chemicals claimed
The agreement provides for a close working relationship between Genzyme and Arecor in developing stable, high strength formulations of labile biomolecules. Both the parties said that the agreement
Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease
Ferenc Darvas, founder and president of board at NanGenex, said: “This is a major milestone in the development of a new class of innovative Nanodrugs that provide fundamental
Hyzaar is a combination medication used in the treatment of high blood pressure. One component, losartan, belongs to a new class of blood pressure medications that work by
The president said that the raw materials are being shipped by air and are on schedule to begin test runs for the production of several generic pharmaceuticals by
According to a research conducted by a group of scientists in partnership with professor Michael Krainer, director of the molecular genetics working group, department of oncology, University Clinic
Sanofi reportedly made an investment of $90m to enhance capacity at its manufacturing facility in Beijing in April 2009, which according to Chris Viehbacher, CEO of the company,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.